The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Headline
The U.S. District Court for the District of Massachusetts yesterday ruled in favor of 25 states and the District of Columbia to vacate the Centers for Medicare…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
The AHA Oct. 20 expressed support for the Addressing Boarding and Crowding in the Emergency Department (ABC-ED) Act (S. 1974), bipartisan legislation designed…
Headline
AHA leaders this week are participating in the International Hospital Federation’s 2026 World Hospital Congress in Seoul, South Korea. On Oct. 20, Bill Gassen,…
Headline
The AHA provided recommendations to the Food and Drug Administration Oct. 19 on potential regulatory frameworks for generative artificial intelligence-enabled…
Headline
An executive order issued by the White House Oct. 19 directs the Department of Health and Human Services, through the National Institutes of Health, to…